Optimized and Scalable LNP Composition for RNA Vaccine Delivery

Thank you

This live web event has ended. Thank you for attending.

Description

Lipid nanoparticle encapsulated RNA (RNA-LNP) vaccines have played a pivotal role in the global response to the COVID-19 pandemic and are now at various stages of development against a wide-range of other infectious diseases. Limited access to potent ionizable lipids, a key component in LNPs, and expertise for formulation and scale-up, present real barriers to entry in this field. To overcome these challenges, we developed and optimized a novel ionizable lipid and a corresponding LNP composition for the delivery of RNA in vaccine applications.
This webinar describes why access to potent ionizable lipids, a key component in LNPs, and expertise for formulation and scale-up are crucial for successful vaccine formulations.

Learning Objectives:

LNP formulation and physicochemical characteristics with both messenger RNA (mRNA) and self-amplifying RNA (saRNA)
In vivo immunogenicity of RNA-LNP vaccines against influenza A and SARS-CoV--2
Overcoming scale-up and process development challenges in vaccine development

Contributors

Natalie Orr, Ph.D.

Natalie Orr is a product development scientist who holds a Ph.D. in pharmaceutical sciences, and a master’s degree in pharmacy from Queen’s University Belfast. Her Ph.D. research was focused on the development of liposomal formulations for the inhaled delivery of antibiotics to treat lung infections in cystic fibrosis. Since completing her PhD, she has continued her research in lipid-based nanoparticles, most recently working with the Perrie group at the University of Strathclyde on lipid nanoparticles in vaccine applications. In her current role at Precision NanoSystems, Natalie supports the research and development of new products, with the over-arching aim of accelerating the development of genomic medicines.

Thank you

Description

Contributors

Natalie Orr, Ph.D.